DocuSign Q1: Lowered Billing Growth Is Just Renewal Timing Issue

  • I reiterate my 'Buy' rating on DocuSign, with a fair value estimate of $95 per share, despite near-term billing growth deceleration. DocuSign's international expansion and growing Intelligent Agreement Management platform are key drivers for sustained high-single-digit revenue growth. Recent go-to-market changes led to lower renewal billings, but I see this as a timing issue, not a demand problem.